Top

BMC Urology

Published in:

Open Access 01-12-2018 | Research article

Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma

Authors: Dong Fang, Shiming He, Gengyan Xiong, Nirmish Singla, Zhenpeng Cao, Lei Zhang, Xuesong Li, Liqun Zhou

Published in: BMC Urology | Issue 1/2018

Abstract

Background

There's no consensus about the difference between renal pelvic and ureteral tumors in terms of clinical features, pathological outcomes, epigenetic biomarkers and prognosis.

Methods

The data of 341 patients with renal pelvic tumors and 271 patients with ureteral tumors who underwent radical nephroureterectomy between 1999 and 2011 were retrospectively reviewed. The clinicopathologic features, gene promoters methylation status and oncologic outcomes were compared. Regression analysis was performed to identify oncologic prognosticators.

Results

Patients with ureteral tumors were relatively older (p = 0.002), and had higher likelihood of pre-operative renal insufficiency (p < 0.001), hypertension (p = 0.038) and hydronephrosis (P < 0.001), while in patients with renal pelvic tumors gross hematuria was more prevalent (p < 0.001). Renal pelvic tumors tended to exhibit non-organ-confined disease (p = 0.004) and larger tumor diameter (p = 0.001), while ureteral tumors had a higher likelihood of exhibiting high grade (p < 0.001) and sessile architecture (p = 0.023). Hypermethylated gene promoters were significantly more prevalent in renal pelvic tumors (p < 0.001), specifically for TMEFF2, GDF15, RASSF1A, SALL3 and ABCC6 (all p < 0.05). Tumor location failed to independently predict cancer-specific survival, overall survival, intravesical or contralateral recurrence (all p > 0.05), while gene methylation status was demonstrated to be an independent prognostic factor.

Conclusion

Renal pelvic tumors and ureteral tumors exhibited significant differences in clinicopathologic characteristics and epigenetic biomarkers. Gene promoter methylation might be an important mechanism in explaining distinct tumor patterns and behaviors in UTUC.

Perez-Utrilla Perez M, Aguilera Bazan A, Alonso Dorrego JM, Viton Herrero R, Cisneros Ledo J, de la Pena Barthel J. Simultaneous cystectomy and Nephroureterectomy due to synchronous upper urinary tract tumors and invasive bladder Cancer: open and laparoscopic approaches. Currt Urol. 2012;6(2):76–81.CrossRef

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMed

Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am. 1980;7(3):569–78.PubMed

Wu Y, Dong Q, Liu L, Han P, Wei Q. The impact of tumor location and multifocality on prognosis for patients with upper tract urothelial carcinoma: a meta-analysis. Sci Rep. 2014;4:6361.CrossRefPubMedPubMedCentral

Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Strobel P, Fernandez M, Karakiewcz P, Shariat SF. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57(6):1072–9.CrossRefPubMed

Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol. 2009;182(5):2177–81.CrossRefPubMed

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H, Miyazaki Y, Obata J, Hoshino K, Shirotake S, Akita H, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Jinzaki M, Oya M. Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol. 2014;21(3):1038–45.CrossRefPubMed

Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, Shariat SF, Kapur P, Lotan Y, Margulis V. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? World J Urol. 2016;34(1):105–12.CrossRefPubMed

Yates DR, Catto JW. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World J Urol. 2013;31(1):21–9.CrossRefPubMed

10.

Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene. 2003;22(54):8699–706.CrossRefPubMed

11.

Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903–10.CrossRefPubMed

12.

Xiong G, Liu J, Tang Q, Fan Y, Fang D, Yang K, Xie F, Zhang M, Zhang L, Liu L, Zhang C, Yao L, Yang L, Ci W, Zhao W, Gong Y, He Q, Gong K, He Z, Wang G, Li X, Guo Y, Zhou L. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics. 2015;7(5):733–44.CrossRefPubMed

13.

Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–44.CrossRefPubMed

14.

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.CrossRefPubMedPubMedCentral

15.

Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007;13(24):7296–304.CrossRefPubMed

16.

Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61(24):8659–63.PubMed

17.

Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, Teixeira MR, Jeronimo C, Lind GE. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010;16(23):5842–51.CrossRefPubMed

18.

Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001;61(18):6688–92.PubMed

19.

Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res. 2013;32:94.CrossRefPubMedPubMedCentral

20.

Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001;61(7):2847–51.PubMed

21.

Seisen T, Granger B, Colin P, Leon P, Utard G, Renard-Penna R, Comperat E, Mozer P, Cussenot O, Shariat SF, Roupret M. A systematic review and meta-analysis of Clinicopathologic factors linked to Intravesical recurrence after radical Nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122–33.CrossRefPubMed

22.

Fang D, Xiong GY, Li XS, Chen XP, Zhang L, Yao L, He ZS, Zhou LQ. Pattern and risk factors of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a large Chinese center experience. J Formos Med Assoc. 2014;113(11):820–7.CrossRefPubMed

Title: Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma
Authors: Dong Fang
Shiming He
Gengyan Xiong
Nirmish Singla
Zhenpeng Cao
Lei Zhang
Xuesong Li
Liqun Zhou
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2018
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-018-0334-7

At a glance: The STEP trials

Springer Medicine

Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Obesity impairs male fertility through long-term effects on spermatogenesis

Daily tadalafil for the chronic phase of stuttering priapism: a case report

How to perform the dusting technique for calcium oxalate stone phantoms during Ho:YAG laser lithotripsy

Laparoscopic radical cystectomy with pelvic re-peritonealization: the technique and initial clinical outcomes

Seminal vesicle abnormalities following prostatic artery embolization for the treatment of benign prostatic hyperplasia

Changes in renal papillary density after hydration therapy in calcium stone formers